Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways

Chinese Medicine

Volumn 5, Issue , 2010, Pages

  Saw, Constance L ^a   Wu, Qing ^a,b   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GINSENG EXTRACT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHINESE MEDICINE; GENE TARGETING; GENETIC CODE; GINSENG; HUMAN; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 77958497927     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-5-37     Document Type: Review

References (77)

1. Gillis CN. Panax ginseng pharmacology: a nitric oxide link?. Biochem Pharmacol 1997, 54(1):1-8. 10.1016/S0006-2952(97)00193-7, 9296344.
2. Yue PY, Mak NK, Cheng YK, Leung KW, Ng TB, Fan DT, Yeung HW, Wong RN. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med 2007, 2:6. 10.1186/1749-8546-2-6, 1876803, 17502003.
3. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004, 9(3):259-274.
4. Saita T, Katano M, Matsunaga H, Kouno I, Fujito H, Mori M. Screening of polyacetylenic alcohols in crude drugs using the ELISA for panaxytriol. Biol Pharm Bull 1995, 18(7):933-937.
5. Matsunaga H, Saita T, Nagumo F, Mori M, Katano M. A possible mechanism for the cytotoxicity of a polyacetylenic alcohol, panaxytriol: inhibition of mitochondrial respiration. Cancer Chemother Pharmacol 1995, 35(4):291-296. 10.1007/BF00689447, 7828271.
6. Yun TK. Panax ginseng--a non-organ-specific cancer preventive?. Lancet Oncol 2001, 2(1):49-55. 10.1016/S1470-2045(00)00196-0, 11905620.
7. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 2009, 48(2):91-104. 10.1002/mc.20465, 2631094, 18618599.
8. Gum SI, Jo SJ, Ahn SH, Kim SG, Kim JT, Shin HM, Cho MK. The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J Ethnopharmacol 2007, 112(3):568-576. 10.1016/j.jep.2007.05.014, 17590295.
9. Ng F, Yun H, Lei X, Danishefsky SJ, Fahey J, Stephenson K, Flexner C, Lee L. (3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment. Tetrahedron Lett 2008, 49(50):7178-7179. 10.1016/j.tetlet.2008.09.169, 2598768, 20011028.
10. Hwang YP, Jeong HG. Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol 2010, 242(1):18-28. 10.1016/j.taap.2009.09.009, 19781563.
11. Morris CA, Avorn J. Internet marketing of herbal products. Jama 2003, 290(11):1505-1509. 10.1001/jama.290.11.1505, 13129992.
12. DeAngelis CD, Fontanarosa PB. Drugs alias dietary supplements. Jama 2003, 290(11):1519-1520. 10.1001/jama.290.11.1519, 13129996.
13. Dietz BM, Liu D, Hagos GK, Yao P, Schinkovitz A, Pro SM, Deng S, Farnsworth NR, Pauli GF, van Breemen RB, Bolton JL. Angelica sinensis and its alkylphthalides induce the detoxification enzyme NAD(P)H: quinone oxidoreductase 1 by alkylating Keap1. Chem Res Toxicol 2008, 21(10):1939-1948. 10.1021/tx8001274, 2615640, 18808158.
14. Yun TK. Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res 2003, 523-524:63-74.
15. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001, 16(Suppl):S28-37.
16. Chang YS, Seo EK, Gyllenhaal C, Block KI. Panax ginseng: a role in cancer therapy?. Integr Cancer Ther 2003, 2(1):13-33. 10.1177/1534735403251167, 12941165.
17. Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009, 16(22):2924-2942. 10.2174/092986709788803204, 2754208, 19689273.
18. Xiang YZ, Shang HC, Gao XM, Zhang BL. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res 2008, 22(7):851-858. 10.1002/ptr.2384, 18567057.
19. Qi LW, Wang CZ, Yuan CS. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010, 80(7):947-954. 10.1016/j.bcp.2010.06.023, 20599804.
20. Ni W, Zhang X, Wang B, Chen Y, Han H, Fan Y, Zhou Y, Tai G. Antitumor activities and immunomodulatory effects of ginseng neutral polysaccharides in combination with 5-fluorouracil. J Med Food 2010, 13(2):270-277. 10.1089/jmf.2009.1119, 20132044.
21. Cheng H, Li S, Fan Y, Gao X, Hao M, Wang J, Zhang X, Tai G, Zhou Y. Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells. Med Oncol 2010,
22. Zeng Y. Adjunctive therapy of Ginseng Polysaccharide for lung cancer. China Pharmaceuticals 2001, 10(6):31-32.
23. Fu W, Chen L, Huang S, Zou H. The role of Panax ginseng polysaccharide injection in chemotherapy of patients with ovarian cancer. Pharm Care & Res 2005, 5(2):169-171.
24. Xie F, Zeng Z, Huang H, Zhao C, Lu T. Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001, 21(5):332-334.
25. Liu J, Sun L, Zhao Y, Zhou T, Zhang J, Sui G, Wu J, Zhou J, Fu L, Lu Q, Liu G, Hui M. Clinical phase II study on immunoimprovement of patients with breast cancer treated by Shenyi capsule. Chin J Clin Oncol 2000, 27(7):534-536.
26. Liu S, Sun L, Ban L, Zhou T. Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Chin Clin Oncol 2007, 12(11):847-849.
27. Wang H, Li X. The application of shengmai injection in malignant tumor. Mod Chin Med 2003, (3):16-17.
28. Berenblum I, Armuth V. Two independent aspects of tumor promotion. Biochim Biophys Acta 1981, 651(1):51-63.
29. Heidelberger C, Freeman AE, Pienta RJ, Sivak A, Bertram JS, Casto BC, Dunkel VC, Francis MW, Kakunaga T, Little JB, Schechtman LM. Cell transformation by chemical agents--a review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 1983, 114(3):283-385.
30. Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009, 66(23):3663-3673. 10.1007/s00018-009-0099-y, 19629388.
31. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444. 10.1038/nature07205, 18650914.
32. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71(10):1397-1421. 10.1016/j.bcp.2006.02.009, 16563357.
33. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007, 64(9):1105-1127. 10.1007/s00018-007-6484-5, 17396224.
34. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985, 45(1):1-8.
35. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007, 595:471-480. full_text, 17569225.
36. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65(11):1631-1652. 10.1007/s00018-008-7452-4, 18324353.
37. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005, 28(3):249-268. 10.1007/BF02977789, 15832810.
38. Valgimigli L, Iori R. Antioxidant and pro-oxidant capacities of ITCs. Environ Mol Mutagen 2009, 50(3):222-237. 10.1002/em.20468, 19197991.
39. Yu S, Kong AN. Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets 2007, 7(5):416-424. 10.2174/156800907781386669, 17691900.
40. Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos 2009, 30(7):345-355. 10.1002/bdd.680, 2782863, 19725016.
41. Yuan JH, Li YQ, Yang XY. Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology 2007, 80(4):269-278. 10.1159/000106447, 17657175.
42. Yuan JH, Li YQ, Yang XY. Protective effects of epigallocatechin gallate on colon preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f ] quinoline in mice. Mol Med 2008, 14(9-10):590-598. 10.2119/2007-00050.Yuan, 2442020, 18596869.
43. Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 2010, 244(1):66-76. 10.1016/j.taap.2009.08.028, 19732782.
44. Khor TO, Yu S, Kong AN. Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med 2008, 74(13):1540-1547. 10.1055/s-0028-1088303, 18937168.
45. Nair S, Li W, Kong AN. Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol Sin 2007, 28(4):459-472. 10.1111/j.1745-7254.2007.00549.x, 17376285.
46. Katoh Y, Iida K, Kang MI, Kobayashi A, Mizukami M, Tong KI, McMahon M, Hayes JD, Itoh K, Yamamoto M. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys 2005, 433(2):342-350. 10.1016/j.abb.2004.10.012, 15581590.
47. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009, 284(20):13291-13295. 10.1074/jbc.R900010200, 2679427, 19182219.
48. Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S, Oo KT, Ma J, Kong AN. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog 2006, 45(11):841-850. 10.1002/mc.20234, 16739127.
49. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008, 60(1):79-127. 10.1124/pr.107.07104, 18323402.
50. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994, 91(21):9926-9930. 10.1073/pnas.91.21.9926, 44930, 7937919.
51. Kwak MK, Wakabayashi N, Kensler TW. Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 2004, 555(1-2):133-148.
52. Jeong WS, Jun M, Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 2006, 8(1-2):99-106. 10.1089/ars.2006.8.99, 16487042.
53. Lee LS, Stephenson KK, Fahey JW, Parsons TL, Lietman PS, Andrade AS, Lei X, Yun H, Soon GH, Shen P, Danlshefsky S, Flexner C. Induction of chemoprotective phase 2 enzymes by ginseng and its components. Planta Med 2009, 75(10):1129-1133. 10.1055/s-0029-1185508, 19326326.
54. Halim M, Yee DJ, Sames D. Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng. J Am Chem Soc 2008, 130(43):14123-14128. 10.1021/ja801245y, 18826220.
55. Park SH, Jang JH, Chen CY, Na HK, Surh YJ. A formulated red ginseng extract rescues PC12 cells from PCB-induced oxidative cell death through Nrf2-mediated upregulation of heme oxygenase-1 and glutamate cysteine ligase. Toxicology 2010, 278(1):131-139.
56. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M, Windust A, Cui T. An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol 2010, 130(2):222-230. 10.1016/j.jep.2010.03.040, 20447451.
57. Kim SH, Park KS, Chang MJ, Sung JH. Effects of Panax ginseng extract on exercise-induced oxidative stress. J Sports Med Phys Fitness 2005, 45(2):178-182.
58. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS. Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol 2008, 48(5):599-609. 10.1177/0091270008314252, 18319359.
59. Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, Xiao C, Zhang B, Gao Y. Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol 2008, 601(1-3):73-78. 10.1016/j.ejphar.2008.10.057, 19022240.
60. Kim J, Cha YN, Surh YJ. A protective role of nuclear erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 2010, 690(1-2):12-23.
61. Lin W, Wu RT, Wu T, Khor TO, Wang H, Kong AN. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol 2008, 76(8):967-973. 10.1016/j.bcp.2008.07.036, 2577694, 18755157.
62. Liu H, Dinkova-Kostova AT, Talalay P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA 2008, 105(41):15926-15931. 10.1073/pnas.0808346105, 2572965, 18838692.
63. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005, 102(12):4584-4589. 10.1073/pnas.0500815102, 555528, 15767573.
64. Ahn YH, Hwang Y, Liu H, Wang XJ, Zhang Y, Stephenson KK, Boronina TN, Cole RN, Dinkova-Kostova AT, Talalay P, Cole PA. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci USA 2010, 107(21):9590-9595. 10.1073/pnas.1004104107, 20439747.
65. Banning A, Florian S, Deubel S, Thalmann S, Muller-Schmehl K, Jacobasch G, Brigelius-Flohe R. GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells. Antioxid Redox Signal 2008, 10(9):1491-1500. 10.1089/ars.2008.2047, 18479189.
66. Park YC, Lee CH, Kang HS, Kim KW, Chung HT, Kim HD. Ginsenoside-Rh1 and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages. Biochem Mol Biol Int 1996, 40(4):751-757.
67. Surh YJ, Na HK, Lee JY, Keum YS. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean Med Sci 2001, 16(Suppl):S38-41.
68. Kim ND, Pokharel YR, Kang KW. Ginsenoside Rd enhances glutathione levels in H4IIE cells via NF-kappaB-dependent gamma-glutamylcysteine ligase induction. Pharmazie 2007, 62(12):933-936.
69. Oh GS, Pae HO, Choi BM, Seo EA, Kim DH, Shin MK, Kim JD, Kim JB, Chung HT. 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett 2004, 205(1):23-29. 10.1016/j.canlet.2003.09.037, 15036657.
70. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002, 2(10):740-749. 10.1038/nrc906, 12360277.
71. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2(9):664-674. 10.1038/nri887, 2668257, 12209135.
72. Nair S, Doh ST, Chan JY, Kong AN, Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 2008, 99(12):2070-2082. 10.1038/sj.bjc.6604703, 2607222, 19050705.
73. Wang H, Khor TO, Saw CL, Lin W, Wu T, Huang Y, Kong AN. Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol Pharm 2010,
74. Kuang X, Scofield VL, Yan M, Stoica G, Liu N, Wong PK. Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res 2009, 1286:174-184. 10.1016/j.brainres.2009.06.007, 19523933.
75. Cho HY, Gladwell W, Wang X, Chorley B, Bell D, Reddy SP, Kleeberger SR. Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med 2010, 182(2):170-182. 10.1164/rccm.200907-1047OC, 20224069.
76. Saw CL, Huang Y, Kong AN. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol 2010, 79(3):421-430. 10.1016/j.bcp.2009.08.030, 19744468.
77. Cheung KL, Khor TO, Kong AN. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res 2009, 26(1):224-231. 10.1007/s11095-008-9734-9, 18841446.